Buradasınız

Anasayfa » Content

Yüksek Ateş, Pansitopeni, Masif Splenomegali Ayırıcı Tanısında Bir Genç Kala-Azar Olgusu ve Lipozomal Amfoterisin B İle Başarıyla Tedavisi

Successful Treatment With Lipozomal Amphotericin B And A Young Kala Azar Cases İn Differential Diagnosis Of Fever, Pancytopenia, Massive Splenomegaly

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2002

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Visseral leishmaniasis (VL) is a chronic infectious disease caused by a protozoan parasite of the genus Leıshmania. It is characterized by intermittent fever, hepatosplenomegaly and pancytopenia. The onset of symptoms may be gradual or sudden. The definitive diagnosis depends on the demonstration of amastigotes in tissue or isolation of the organism in culture. In 54-86 percent of the cases, amastigotes are seen Wright or Giemsa-stained bone marrow aspirations. Liposomal amphotericin B is known to be effective against VL. Here we report a VL case who were succesfully treated using 0.8 mg/kg/day liposomal amphotericin B (total dose, 2300 mg).
Bookmark/Search this post with
Abstract (Original Language): 
Visseral Leishmaniazis (VL), leishmania cinsinden protozoan olan parazitin neden olduğu kronik bir hastalıktır. Hastalık aralıklı ateş hepatosplenomegali ve pansitopeniyle karekterizedir. Semptomların başlangıcı dereceli ya da anidir. Kesin tanısı kültürde organizmaların izolasyonu, dokuda amastigotların gösterilmesine bağlıdır. Amastigotlar Wright ve Giemsa boyalarında kemik iliği aspiratlarında vakaların %54-86’sında görülmektedir. Tedavide Lipozomal amfoterisin B’nin VL’e etkili olduğu bilinmektedir. Biz burada 0.8 mg/kg/gün (total doz 2300 mg) lipozomal amfoterisin B ile başarıyla tedavi edilen VL’li bir olguyu bildiriyoruz.
FULL TEXT (PDF): 
PDF icon arastirmax-yuksek-ates-pansitopeni-masif-splenomegali-ayirici-tanisinda-bir-genc-kala-azar-olgusu-lipozomal-amfoterisin-b-ile-basariyla-tedavisi.pdf
  • 3
121-124
  • Turkish

REFERENCES

References: 

1. Minodier P, Garnier JM. Childhood visceral leishmaniasis in
Provence. Arch Pediatr 2000;7: 572- 7.
2. Büyükaşık Y, İleri NS, Haznedaroğlu IC, Demiroğlu H, Dündar
S. Fever, hepatosplenomegaly and pancytopenia in a patient
living in the Mediterranean region. Postgrad Med J 1998;74: 237-
9.
3. Colovic MD, Jankovic GM, Colovic NR, Martinovic VC. Kalaazar and myelodysplastic syndrome in the same patient. Haema
2002;5:246-8.
4. Pearson RD, Sousa AQ. Leishmania species:Visceral (KalaAzar), cutaneous and mucasal leishmaniasis. In: Mandell GL,
Bennett JE, Dolin R (eds). Principal and practice ınfectious
diseases. Fourth Edition. Livingstone:Churchill Co, 1995. 2428-
38.
5. C.Petit, V.Yardley, F.Gaboriau, J.Bolard, and S.L.Croft. Activity
of a Heat-Induced Reformulation of Amphotericin B
Deoxycholate (Fungizone) against Leıshmania donovani.
Antimicrob Agents Chemother 1999;43:390-2.
6. Henry W Murray. Clinical and Experimental Advances in
Treatment of Visceral Leishmaniasis. Antimicrob Agents
Chemother 2001;45: 2185-97.
7. Martin S, Gambel J, Jackson J, Anonson N, Gupta R, Rowton E,
Perich M, McEvoy P, Bermon J, Magill A, Hoke C.
Leıshmaniasis in the United States military. Mil Med
1998;163:801-7. V. Özkocaman
124
8. Croft SL, Davidson RN, Thornton EA. Liposomal amphotericin B
in the treatment of visceral leishmaniasis. J.Antimicrob
Chemother 1991;28:111-8.
9. Davidson RN, Di Martino L, Gradoni L, Giacchino R, Russo R,
Gaeta GB, Penpinello R, Scott S, Raimondi F, Cascio A.
Liposomal amphotericin B (AmBisome) in mediterranean visceral
leishmaniasis: a multicentre trial. Q J Med 1994;87:75-81.
10. Rodriguez Wilhelmi P, Panizo C, Ruza E, Rocha E. Treatment of
visceral leishmaniasis with liposomal amphotericin B in three
immunocompromised patients. Med Clin 2001;116:37-8.
11. Amato V.S, Nicodemo A.C, Amate J.G, Boulos M and Amato
Neto V. Mucocutaneous leishmaniasis associated with HIV
infection treated successfully with liposomal amphotericin B
(AmBisome). J Antimicrobial Chemother 2000;46:341-2.
12. Pal C, Raha M, Basu A, Roy KC, Gupta A, Ghosh M, Sahn NP,
Banerjee S, Mandal NB, Bandyopadhyay S. Combination therapy
with indolylquinoline derivative and sodium antimony glucanate
cures established visceral leishmaniasis in hamsters. Antimicrob
Agents Chemother 2002;46:259-61.
13. Brogden RN, Goa KL, Coukell AJ. Amphotericin-B colloidal
dispersion. A review of its use against systemic fungal infections
and visceral leishmaniasis. Drugs 1998;56:365-83.
14. Boletis JN, Pefanis A, Stathakis C, Helioti H, Kostakis A,
Giamarellou H. Visceral leishmaniasis in renal transplant
recipients: successful treatment with liposomal amphotericin B
(AmBisome). Clin Infect Dis 1999;28:1308-9.
15. Davidson RN, Di martino L, Gradoni L, Giacchino R, Gaeta GB,
Pempinello R, Scoth S, Cascio A, Castagnola E, Maisto A,
Gramiccia M, di Caprio D, Wilkinson RJ, Bryceson AD. Shortcourse treatment of visceral leishmaniasis with liposomal
amphotericin B (AmBisome) Clin Infect Dis 1996;22:938-43.
16. Borrelli P, Imperato A, Murdaca G, Scudeletti M. Liposomal
amphotericin B as first line and secondary prophylactic treatment
for visceral leishmaniasis in a patient infected with HIV. Ann Ital
Med Int 2000;15:169-71.
17. Torre-Cisneros J, Villmveva JL. Efficacy of liposomal
amphotericin B in the treatment of visceral leishmaniasis in
patients coinfected with the human immunodeficiency virus. Clin
Infect Dis 1995;20:191.
18. Coukell AJ, Brogden RN. Liposomal amphotericin B Therapeutic
use in the management of fungal İnfections and visceral
leishmaniasis. Drugs 1998;55:585-612.

Thank you for copying data from http://www.arastirmax.com